Table 1.
Clinical characteristics of patients with Gram-negative bloodstream infection based on site of acquisition
| Variable | Healthcare-associated N=306 |
Community-acquired N=427 |
p value* |
|---|---|---|---|
| Age: median (IQR) | 73 (51–83) | 66 (45–79) | <0.001 |
| Female sex, n (%) | 168 (54.9) | 253 (59.3) | 0.24 |
| Primary source, n (%) | <0.001 | ||
| Urinary tract | 166 (54.2) | 281 (65.8) | |
| Gastrointestinal tract | 29 (9.5) | 61 (14.3) | |
| Respiratory tract | 26 (8.5) | 22 (5.2) | |
| Skin and soft tissue | 10 (3.3) | 9 (2.1) | |
| Central venous catheter-related | 10 (3.3) | 0 (0) | |
| Other | 3 (1.0) | 4 (0.9) | |
| Unknown | 62 (20.3) | 50 (11.7) | |
| Microbiology, n (%) | <0.001 | ||
| Escherichia coli | 145 (47.4) | 271 (63.5) | |
| Klebsiella pneumoniae | 45 (14.7) | 48 (11.2) | |
| Pseudomonas aeruginosa | 28 (9.2) | 12 (2.8) | |
| Proteus mirabilis | 13 (4.2) | 11 (2.6) | |
| Enterobacter species | 20 (6.5) | 8 (1.9) | |
| Citrobacter species | 6 (2.0) | 4 (0.9) | |
| Serratia species | 5 (1.6) | 6 (1.4) | |
| Other | 44 (14.4) | 67 (15.7) | |
| Fluoroquinolone resistancea | 24/293 (8.2) | 15/406 (3.7) | 0.01 |
| Third-generation cephalosporin resistancea | 13/293 (4.4) | 11/405 (2.7) | 0.22 |
IQR: interquartile range, CI: confidence intervals
*
Chi-squared test was used to calculate p values for categorical variables and Wilcoxon rank-sum test for continuous variables
a
Among isolates with available in vitro antimicrobial susceptibility results to fluoroquinolones and third-generation cephalosporins